Breeze Holdings Acquisition Corp. shareholders approve the business combination with YD Biopharma Limited.
The combined company will be named YD Bio Limited and is expected to trade on Nasdaq under the ticker symbol "YDES".
The closing of the transaction is expected to occur within the next two weeks.
Business Combination Approval
The Business Combination Proposal was approved by a significant majority of shareholders, signaling confidence in the merger with YD Biopharma.
Ticker Symbol Change
Upon closing, the combined company will operate under the new ticker symbol "YDES" on the Nasdaq Stock Market.
Closing Timeline
The transaction is anticipated to close within the next two weeks, pending the fulfillment of standard closing conditions.
- The approval of the business combination indicates a favorable outlook for the future of the combined entity.
- The new company, YD Bio Limited, is poised to leverage YD Biopharma's expertise in innovative vaccines and therapeutic biologics for infectious diseases.
- Trading on Nasdaq under the ticker symbol "YDES" will enhance visibility and accessibility for investors in the newly formed company.
The approval by Breeze Holdings Acquisition Corp. shareholders marks a crucial step towards the successful merger with YD Biopharma Limited. The combined entity, YD Bio Limited, is set to embark on a new chapter of growth and innovation in the biopharmaceutical sector.